Business Context and Reporting Period
Company: Baxter International Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2000
Business Overview: Baxter operates in three primary segments: I.V. Systems/Medical Products, BioScience, and Renal. The company spun off its cardiovascular business (Edwards Lifesciences Corporation) on March 31, 2000, which is now reported as a discontinued operation.
Key Financial Metrics
| Metric (in millions) | Three Months Ended Sep 30, 2000 | Nine Months Ended Sep 30, 2000 | Nine Months Ended Sep 30, 1999 |
|---|---|---|---|
| Net Sales | $1,687 | $4,964 | $4,611 |
| Operating Income | $328 | $638 | $822 |
| Net Income | $231 | $470 | $568 |
| Diluted EPS | $0.77 | $1.58 | $1.92 |
| Cash Flow from Operations | N/A | $447 | $461 |
| Capital Expenditures | N/A | ($398) | ($394) |
| Total Debt (Short + Long Term) | $2,694 | $2,694 | $2,856 |
| Cash and Equivalents | $568 | $568 | $825 |
Note: Total Debt calculated as Short-term debt ($428M) + Current maturities of long-term debt ($20M) + Long-term debt ($2,246M). 1999 figures derived from Dec 31, 1999 balance sheet for comparison.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 6% for the quarter and 8% year-to-date compared to 1999. Excluding currency fluctuations, sales growth was 10% for the quarter and 11% year-to-date.
- Profitability Decline: Operating income decreased 22% year-to-date ($638M vs. $822M) and Net Income decreased 17% ($470M vs. $568M). This decline is primarily driven by a one-time charge of $286 million for in-process research and development (IPR&D) and acquisition-related costs.
- Discontinued Operations: Income from discontinued operations dropped significantly due to the March 2000 spin-off of the cardiovascular business. The 1999 period included $47M in income from this segment, whereas 2000 reflects only $2M (net of distribution costs).
- Acquisitions: Significant activity included the acquisition of North American Vaccine, Inc. (NAV) for ~$312M and Althin Medical A.B. for ~$86M. The NAV acquisition resulted in a $250M immediate expense for IPR&D.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Objectives: Management aims for 10% net sales growth and mid-teens net earnings growth (excluding IPR&D charges). Operational cash flow target is $500M after capital improvements and R&D.
- Performance vs. Objectives: Year-to-date sales growth of 8% (11% constant currency) is slightly below the 10% target. Net earnings from continuing operations increased 18% year-to-date when excluding the IPR&D charge, exceeding the mid-teens target.
- Segment Drivers:
- BioScience: Strong growth in plasma-derived products (Gammagard) and vaccines (NAV acquisition). Recombinant product sales declined in Q3 due to supply constraints, expected to resolve in Q4.
- Renal: Growth driven by international markets and the Althin acquisition.
- I.V. Systems: Growth driven by anesthesia products (generic Propofol) and electronic infusion pumps.
Risks and Contingencies
- Legal Proceedings:
- Mammary Implants: Defendant in 722 lawsuits and 327 claims (approx. 1,861 plaintiffs) regarding silicone implants formerly manufactured by Heyer-Schulte. A class action settlement (Lindsey) is in place, but opt-out plaintiffs remain.
- Plasma-Based Therapies: Defendant in lawsuits regarding HIV infections from factor concentrates (late 1970s-mid 1980s). A U.S. federal settlement is approved; international cases (Japan, Italy, etc.) are ongoing.
- Gammagard Hepatitis C: Defendant in 36 lawsuits regarding Hepatitis C infections. A U.S. class action settlement was approved in September 2000.
- Accounting Changes: The company plans to adopt FASB Statement No. 133 (Derivatives) on January 1, 2001. The impact is not fully determinable but will be recorded as a cumulative effect of an accounting change.
- Currency: A strengthening U.S. dollar negatively impacts reported sales and earnings growth.
Investor Verification Checklist
- IPR&D Charge Impact: Verify the long-term commercial viability of the $250M IPR&D charge related to North American Vaccine, Inc., as future returns depend on successful product development.
- Legal Reserves Adequacy: Assess whether current reserves for mammary implant and plasma therapy litigation are sufficient given the number of opt-out plaintiffs and international claims.
- Supply Chain Constraints: Monitor the resolution of supply constraints in the BioScience segment's recombinant products to ensure Q4 sales recovery.
- Currency Hedging: Review the effectiveness of hedging strategies given the volatility of the Euro and Yen against the U.S. dollar.
- Debt Structure: Confirm the net-debt-to-capital ratio (42.0% at Sep 30, 2000) remains within management's target range as debt levels fluctuate.